Prolongation of Near-Normoglycemic Remission in Black NIDDM Subjects With Chronic Low-Dose Sulfonylurea Treatment
The DOI matches its Crossref record.
Abstract
Microvascular and neuropathic complications of diabetes mellitus can be significantly decreased by long-term, near-normoglycemic regulation in patients with insulin-dependent diabetes mellitus. Prevention or delay of onset of hyperglycemia in non-insulin-dependent diabetes mellitus (NIDDM) patients should reduce morbidity and mortality from these complications. NIDDM can be nearly normoglycemic when diagnosed by screening before its symptomatic stage or when clinically hyperglycemic NIDDM goes into remission. One potential strategy to delay the onset of hyperglycemia in individuals at high risk is chronic low-dose sulfonylurea therapy. Thirty black NIDDM subjects who recently had developed near-normoglycemia were followed with no treatment or were randomly assigned to a 3-year, double-blind glipizide or placebo treatment. Baseline and follow-up parameters included fasting plasma glucose (FPG), HbA1c, plasma insulin, and glucose responses to an oral glucose tolerance test and insulin action, as determined by the euglycemic insulin clamp. Baseline FPG and HbA1c for all three groups were 107 mg/dl and 4.7%, respectively. Relapse to hyperglycemia was defined as an FPG level ≥ 140 mg/dl on several consecutive visits or an FPG level ≥ 140 mg/dl and symptoms of hyperglycemia. During the course of the treatment and follow-up, hyperglycemia occurred in 6 of 10 subjects in the no treatment group, 6 of 10 in the placebo group, and 2 of 10 in the glipizide treatment group. Prolongation of near-normoglycemia was significantly (P < 0.05) increased by low-dose (2.5 mg/day) glipizide compared with placebo treatment. Low-dose sulfonylurea therapy delays the onset of hyperglycemia in NIDDM subjects in remission and may be a useful method to delay the onset of NIDDM in high-risk individuals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The evolution of diabetic ketoacidosis: An update of its etiology, pathogenesis and management
Nyenwe, E. A., & Kitabchi, A. E. (2016) · Metabolism · doi:10.1016/j.metabol.2015.12.007 · Cited by 309
Ilkova, H., Glaser, B., Tunçkale, A., Bagriaçik, N., & Cerasi, E. (1997) · Diabetes Care · doi:10.2337/diacare.20.9.1353 · Cited by 269
Ketosis-prone diabetes (Flatbush diabetes): an emerging worldwide clinically important entity
Lebovitz, H. E., & Banerji, M. A. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1075-4 · Cited by 98
Self-citationDiabetic ketoacidosis: A common debut of diabetes among African Americans with type 2 diabetes
Vellanki, P., & Umpierrez, G. E. (2017) · Endocrine Practice · doi:10.4158/ep161679.ra · Cited by 73
Vellanki, P., Smiley, D. D., Stefanovski, D., Anzola, I., Duan, W., Hudson, M., Peng, L., Pasquel, F. J., & Umpierrez, G. E. (2016) · Diabetes Care · doi:10.2337/dc16-0406 · Cited by 28
Metadata
- Authors
- Banerji, M. A., Chaiken, R. L., & Lebovitz, H. E.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 1995-04-01
- Volume
- 44
- Issue
- 4
- Pages
- 466-470
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2093957604
- Cited by
- 49
- References
- 0
- FWCI
- 0.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prolongation of Near-Normoglycemic Remission in Black NIDDM Subjects With Chronic Low-Dose Sulfonylurea Treatment. https://app.cochat.ai/papers/10.2337/diab.44.4.466
- The paper
- Banerji, M. A., Chaiken, R. L., & Lebovitz, H. E. (1995). Prolongation of Near-Normoglycemic Remission in Black NIDDM Subjects With Chronic Low-Dose Sulfonylurea Treatment. Diabetes. https://doi.org/10.2337/diab.44.4.466
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.